68Ga-FAPI-04 PET/CT在FDG亲和力较低的乳腺癌患者中的头对头比较研究
这项前瞻性研究纳入24例乳腺原发灶FDG摄取相对较低或怀疑淋巴结或远处转移的乳腺癌女性,在同一周内分别行18F-FDG PET/CT与68Ga-FAPI-04 PET/CT,比较原发灶及转移灶的SUVmax与病灶数量。结果显示68Ga-FAPI-04在原发灶SUVmax更高,并额外检出乳腺病灶、腋窝及区域淋巴结受累和远处转移灶。作者认为该方法可能通过提高淋巴结分期而有助于治疗管理。
要点
- 68Ga-FAPI-04在原发灶的摄取高于18F-FDG,SUVmax均值17.1±7.9 vs 6.3±3.9(P<0.001)。
- 68Ga-FAPI-04额外检出29.2%(7例)患者的乳腺病灶,8.3%(2例)原发灶仅FAPI摄取。
- 68Ga-FAPI-04检出更多腋窝淋巴结受累及锁骨下、锁骨上、内乳淋巴结,可能提高淋巴结分期。
核心结论
- 在FDG亲和力较低的乳腺癌患者中,68Ga-FAPI-04 PET/CT较18F-FDG PET/CT显示原发肿瘤的敏感性更高、SUVmax更高。
- 作者认为该方法可能通过提高淋巴结分期而有助于患者的治疗管理。
研究设计与样本
- 前瞻性研究,纳入24例中位年龄45岁(范围36-67岁)的乳腺癌女性,初次分期行18F-FDG PET/CT并在同一周内行68Ga-FAPI-04 PET/CT。
- 原发肿瘤组织学亚型为11例浸润性小叶癌、8例浸润性导管癌和5例黏液癌。
- 从两种影像记录原发肿瘤及局部区域和远处转移灶的SUVmax与病灶数量并进行统计学比较。
主要发现
- 所有原发肿瘤病灶的68Ga-FAPI-04摄取(均值17.1±7.9;范围7.4-38.5)高于18F-FDG(均值6.3±3.9;范围1.5-20.5)(P<0.001,Z=4.107)。
- 29.2%(7例)的患者检出额外的68Ga-FAPI-04摄取乳腺病灶;8.3%(2例)的患者原发灶仅显示68Ga-FAPI-04摄取。
- 25%(6例)的患者在68Ga-FAPI-04 PET/CT上显示更多淋巴结受累且同侧腋窝摄取更强烈。
- 仅68Ga-FAPI-04 PET/CT检出4例(16.7%)锁骨下(第3站)淋巴结、1例锁骨上淋巴结和1例内乳淋巴结。
- 1例肺和骨转移患者中68Ga-FAPI-04摄取更高,且肺结节仅显示68Ga-FAPI-04摄取。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this prospective study, PET findings of 18 F-FDG PET/CT in breast cancer staging were compared with 68 Ga-FAP inhibitor (FAPI) 04 PET/CT findings in selected cases with relatively low 18 F-FDG uptake in the primary tumor or with suspected nodal or distant metastases. PATIENTS AND METHODS: Twenty-four women with a median age of 45 years (range, 36-67 years) who underwent initial staging 18 F-FDG PET/CT for breast cancer underwent 68 Ga-FAPI-04 PET/CT imaging within the same week. SUV max and quantities of primary tumors and locoregional and distant metastatic lesions were recorded from both images, and these data were compared statistically. RESULTS: The histological subtypes of primary tumors were 11 invasive lobular, 8 invasive ductal, and 5 mucinous subtypes. More intense 68 Ga-FAPI-04 uptake (mean, 17.1 ± 7.9; 7.4-38.5) was detected in all primary tumoral lesions compared with 18 F-FDG (mean, 6.3 ± 3.9; 1.5-20.5) ( P = <0.001, Z = 4.107). Additional lesions showing 68 Ga-FAPI-04 uptake in the breast were detected in 29.2% (n = 7) of patients. In 8.3% (n = 2) of the patients, the primary lesion showed only 68 Ga-FAPI-04 uptake. In 68 Ga-FAPI-04 PET/CT, 25% (n = 6) of the patients showed more lymph node involvement and more intense uptake in the ipsilateral axilla. In addition, infraclavicular (level 3) lymph nodes in 4 patients (16.7%), supraclavicular lymph nodes in 1 patient, and internal mammary lymph nodes in 1 patient were detected only on 68 Ga-FAPI-04 PET/CT. In a patient with lung and bone metastases, 68 Ga-FAPI-04 uptake was higher, and the lung nodule showed only 68 Ga-FAPI-04 uptake. CONCLUSIONS: In selected low-FDG-affinity breast cancer patients, 68 Ga-FAPI-04 PET/CT showed the primary tumor with higher sensitivity and higher SUV max values compared with 18 F-FDG PET/CT. In addition, it is believed that this method may contribute to the management of patients' treatment by increasing the nodal stage.
引用
- Alçın G, Arslan E, Aksoy T, et al. 68 Ga-FAPI-04 PET/CT in Selected Breast Cancer Patients With Low FDG Affinity : A Head-to-Head Comparative Study. Clin Nucl Med. 2023. PMID: 37351868. doi:10.1097/RLU.0000000000004751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。